| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 05/22/2003 | WO2002098438A9 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 05/22/2003 | WO2002097116A3 Delivery system for nucleic acids |
| 05/22/2003 | WO2002096362A3 Method for treating fibrotic diseases or other indications vi |
| 05/22/2003 | WO2002085886A3 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions |
| 05/22/2003 | WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
| 05/22/2003 | WO2002030924A9 Quinazoline derivatives with anti-tumour activity |
| 05/22/2003 | WO2002024187A3 Treatment of diseases with adamantane derivatives |
| 05/22/2003 | WO2002024176A3 Treatment of tinnitus |
| 05/22/2003 | WO2000037429A3 INHIBITORS OF α4β1 MEDIATED CELL ADHESION |
| 05/22/2003 | US20030096850 Treating infections by administration of oxazolidinones |
| 05/22/2003 | US20030096844 Cannabinoid receptor ligands |
| 05/22/2003 | US20030096840 Granule formulation |
| 05/22/2003 | US20030096833 Use in inhibiting inflammation, cell death and in treating shock and reperfusion injuries |
| 05/22/2003 | US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors |
| 05/22/2003 | US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition |
| 05/22/2003 | US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents |
| 05/22/2003 | US20030096812 Such as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections |
| 05/22/2003 | US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders |
| 05/22/2003 | US20030096758 Anticarcinogenic agents |
| 05/22/2003 | US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/22/2003 | US20030096737 Caspase inhibitors and uses thereof |
| 05/22/2003 | US20030096413 Storage of corneas in culture; obtain nutrient broth containing nerve growth factor, deposit corneas in broth, store tissue |
| 05/22/2003 | US20030096370 Gram negative bacterial protein for use in the prevention and treatment of bacterial infection |
| 05/22/2003 | US20030096029 Remedies for allergic diseases and process for producing the same |
| 05/22/2003 | CA2467267A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase |
| 05/22/2003 | CA2466519A1 Method for treating autoimmune diseases |
| 05/22/2003 | CA2466465A1 Nk1 antagonists |
| 05/22/2003 | CA2466440A1 Cannabinoid receptor ligands |
| 05/22/2003 | CA2466344A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
| 05/22/2003 | CA2465893A1 Polycyclic guanine derivative phosphodiesterase v inhibitors |
| 05/22/2003 | CA2464863A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 05/22/2003 | CA2464861A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 05/22/2003 | CA2464347A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 05/22/2003 | CA2460959A1 Enzymes |
| 05/21/2003 | EP1312675A1 Protein induced by homogeneous blood transfusion and dna encoding the same |
| 05/21/2003 | EP1312601A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 05/21/2003 | EP1312380A1 Aseptics |
| 05/21/2003 | EP1312366A1 Aqueous pharmaceutical compositions |
| 05/21/2003 | EP1312356A1 Aqueous suspension preparations |
| 05/21/2003 | EP1311543A1 T cell receptor v beta-d beta-j beta sequence and methods for its detection |
| 05/21/2003 | EP1311534A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 05/21/2003 | EP1311533A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 05/21/2003 | EP1311532A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 05/21/2003 | EP1311500A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 05/21/2003 | EP1311489A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 05/21/2003 | EP1311488A1 Substituted imidazoles as tafia inhibitors |
| 05/21/2003 | EP1311484A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 05/21/2003 | EP1311482A2 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 05/21/2003 | EP1311478A1 Novel thiourea compounds and the pharmaceutical compositions containing the same |
| 05/21/2003 | EP1311299A1 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 05/21/2003 | EP1311297A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 05/21/2003 | EP1311287A2 Transglutaminase for inhibiting angiogenesis |
| 05/21/2003 | EP1311263A2 Fused pyrrolocarbazoles against inflammation |
| 05/21/2003 | EP1311259A2 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent |
| 05/21/2003 | EP1200066B1 Aqueous nasal formulation |
| 05/21/2003 | EP1005369B1 Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy |
| 05/21/2003 | EP0878200B1 Therapeutic agent for ophthalmic diseases |
| 05/21/2003 | EP0797442B1 Treatment of optic neuritis |
| 05/21/2003 | EP0706394B1 Use of a compostion comprising histamine phosphate for the manufacture of a medicament for the topical treatment of epithelial inflammation or lesions |
| 05/21/2003 | CN1419559A Tricyclic protein kinase inhibitors |
| 05/21/2003 | CN1419554A Process for preparing crystalline form 1 of cabergoline |
| 05/21/2003 | CN1419552A 2-amino-3-(alkyl)-pyrimidone derivatives as GSKS beta. inhibitors |
| 05/21/2003 | CN1419548A 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhbitors of cell-cycle kinases |
| 05/21/2003 | CN1419539A Amidino compound and salts thereof useful as nitric oxide synahase inhibitors |
| 05/21/2003 | CN1419438A Cosmetic and pharmaceutical compositions and methods usin 2-decarboxy-2-phophinico derivatives |
| 05/21/2003 | CN1109031C Bicycle-aromatic compound |
| 05/21/2003 | CN1108822C Pharmaceutical composition containing lornoxicam and disodic salt of EDTA |
| 05/21/2003 | CN1108813C Detoxicating stasis-dispersing inflammation-relieving antalgic and refreshing medicine and its preparing process |
| 05/20/2003 | US6566398 Method for treatment of external secretion disorders |
| 05/20/2003 | US6566370 Administering decahydroisoquinoline-3-carboxylic acid derivative for therapy of migraine |
| 05/20/2003 | US6566366 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| 05/20/2003 | US6566363 5-amino-3-substituted-pyrazolo(4,5-d)thiazole compounds that mediate and/or inhibit the activity of cyclin-dependent kinases, useful for treating cancer, angiogenesis and cellular proliferation |
| 05/20/2003 | CA2234239C Indole carbamates as leukotriene antagonists |
| 05/20/2003 | CA2070524C Retinoids substituted by a dithiane cyclic and their use, process for the preparation of these compounds, cosmetic and pharmaceutical compositions containing them and therapeutical use of said compositions |
| 05/15/2003 | WO2003040366A2 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 05/15/2003 | WO2003040333A2 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof |
| 05/15/2003 | WO2003040147A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________ |
| 05/15/2003 | WO2003040138A1 Dimeric compounds and their use as anti-viral agents |
| 05/15/2003 | WO2003040126A1 φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS |
| 05/15/2003 | WO2003040119A1 Angiogenesis inhibitors |
| 05/15/2003 | WO2003040118A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 05/15/2003 | WO2003040117A1 Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| 05/15/2003 | WO2003040115A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
| 05/15/2003 | WO2003040102A1 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
| 05/15/2003 | WO2003040101A1 Anthranilic acid amides and pharmaceutical use thereof |
| 05/15/2003 | WO2003040097A1 Nitrogenous compounds, production process, and method of use thereof |
| 05/15/2003 | WO2003040084A1 Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists |
| 05/15/2003 | WO2003040080A2 Lipoxin a4 analogs |
| 05/15/2003 | WO2003039577A1 Remedies for dry eye and diseases associated with dry eye |
| 05/15/2003 | WO2003039575A2 Use of reelin, gas6, and protein s in the treatment of neural disorders |
| 05/15/2003 | WO2003039573A1 TARGETING THE REVERSE MODE OF THE Na+/Ca2+ EXCHANGER FOR THE TREATMENT OF OPTIC NEUROPATHY ASSOCIATED WITH GLAUCOMA AND ISCHEMIC OPTIC NEUROPATHY |
| 05/15/2003 | WO2003039548A1 Hydrazono-malonitriles |
| 05/15/2003 | WO2003039546A1 New uses for anti-malarial therapeutic agents |
| 05/15/2003 | WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 05/15/2003 | WO2003039481A2 Adipose tissue-derived stromal cells for the repair of corneal and intra-orbital defects and uses thereof |
| 05/15/2003 | WO2003039473A2 Method for treating or preventing inflammatory diseases |
| 05/15/2003 | WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
| 05/15/2003 | WO2003039404A2 Methods for treating ocular neovascular diseases |
| 05/15/2003 | WO2003039231A2 Compounds and methods for treating transplant rejection |
| 05/15/2003 | WO2002097032A3 Proteins associated with cell growth, differentiation, and death |